Volume 11, Issue 3, Pages 278-288 (January 2009) Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults Rosa Gonzalo-Daganzo, Carmen Regidor, Trinidad Martín-Donaire, Miguel Angel Rico, Guiomar Bautista, Isabel Krsnik, Rafael Forés, Emilio Ojeda, Isabel Sanjuán, José A. García-Marco, Belén Navarro, Santiago Gil, Rocío Sánchez, Nuria Panadero, Yolanda Gutiérrez, Miguel García-Berciano, Nuria Pérez, Isabel Millán, Rafael Cabrera, Manuel N. Fernández Cytotherapy Volume 11, Issue 3, Pages 278-288 (January 2009) DOI: 10.1080/14653240902807018 Copyright © 2009 International Society for Cellular Therapy Terms and Conditions
Figure 1 (A) Cumulative incidence of engraftment of granulocytes (ANC >500), CB granulocytes (CB ANC >500) and CB full chimerism in the MSC group of patients (n=9). (B) Cumulative incidence of engraftment of granulocytes (ANC >500), CB granulocytes (CB ANC >500) and CB full chimerism in the control group (non-MSC) of patients (n=46). Cytotherapy 2009 11, 278-288DOI: (10.1080/14653240902807018) Copyright © 2009 International Society for Cellular Therapy Terms and Conditions
Figure 2 (A) Cumulative incidence of engraftment of platelets (>20×109 /L; >50×109/L) in the MSC group of patients (n=9). (B) Cumulative incidence of engraftment of platelets (>20×109/L; >50×109/L) in the control group (non-MSC) of patients (n=46). Cytotherapy 2009 11, 278-288DOI: (10.1080/14653240902807018) Copyright © 2009 International Society for Cellular Therapy Terms and Conditions
Figure 3 (A) Kaplan–Meier probability of survival of MSC and control (non MSC) groups. (B) Cumulative incidence of TRM of MSC and control (non-MSC) groups. Cytotherapy 2009 11, 278-288DOI: (10.1080/14653240902807018) Copyright © 2009 International Society for Cellular Therapy Terms and Conditions